Compare ERII & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | PRTA |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 526.7M |
| IPO Year | 2008 | 2013 |
| Metric | ERII | PRTA |
|---|---|---|
| Price | $8.11 | $10.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $17.07 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.3M | 486.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $134,987,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | ★ N/A | $16.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.14 | $4.53 |
| 52 Week High | $18.31 | $11.80 |
| Indicator | ERII | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 52.24 |
| Support Level | N/A | $9.81 |
| Resistance Level | $11.58 | $10.55 |
| Average True Range (ATR) | 0.42 | 0.53 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 1.61 | 62.90 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.